Page last updated: 2024-11-08

desosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desosamine: RN given for (D-xylo)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID168997
CHEBI ID32540
SCHEMBL ID136024
MeSH IDM0285597

Synonyms (16)

Synonym
CHEBI:32540
desosamine
d-xylo-hexose, 3,4,6-trideoxy-3-(dimethylamino)-
5779-39-5
3,4,6-trideoxy-3-dimethylamino-d-xylo-hexose
3,4,6-trideoxy-3-(dimethylamino)-d-xylo-hexose
unii-3nr0662443
3nr0662443 ,
SCHEMBL136024
d-desosamine
desosamine [mi]
pikrocin
3,4,6-trideoxy-3-dimethylamino-d-xylohexose
VTJCSBJRQLZNHE-CSMHCCOUSA-N
DTXSID90206478
Q5264872

Research Excerpts

Overview

Desosamine is a 3-(dimethylamino)-3,4,6-trideoxyhexose found in certain macrolide antibiotics such as erythromycin.

ExcerptReferenceRelevance
"Desosamine is a 3-(dimethylamino)-3,4,6-trideoxyhexose found in certain macrolide antibiotics such as the commonly prescribed erythromycin. "( Molecular architecture of DesV from Streptomyces venezuelae: a PLP-dependent transaminase involved in the biosynthesis of the unusual sugar desosamine.
Burgie, ES; Holden, HM; Thoden, JB, 2007
)
1.98
"Desosamine is a 3-(dimethylamino)-3,4,6-trideoxyhexose found, for example, in such macrolide antibiotics as erthyromycin, azithromycin, and clarithromycin. "( Molecular architecture of DesI: a key enzyme in the biosynthesis of desosamine.
Burgie, ES; Holden, HM, 2007
)
2.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino sugarAny sugar having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (6.12)18.2507
2000's28 (57.14)29.6817
2010's17 (34.69)24.3611
2020's1 (2.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.45 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (95.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]